| Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms A Prestipino, AJ Emhardt, K Aumann, D O’Sullivan, SP Gorantla, ... Science translational medicine 10 (429), eaam7729, 2018 | 221 | 2018 |
| Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both S Koschmieder, TI Mughal, HC Hasselbalch, G Barosi, P Valent, ... Leukemia 30 (5), 1018-1024, 2016 | 162 | 2016 |
| LSD1 inhibition prolongs survival in mouse models of MPN by selectively targeting the disease clone JS Jutzi, M Kleppe, J Dias, HF Staehle, K Shank, J Teruya-Feldstein, ... Hemasphere 2 (3), e54, 2018 | 91 | 2018 |
| MPN patients harbor recurrent truncating mutations in transcription factor NF-E2 JS Jutzi, R Bogeska, G Nikoloski, CA Schmid, TS Seeger, F Stegelmann, ... Journal of Experimental Medicine 210 (5), 1003-1019, 2013 | 88 | 2013 |
| A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2 KB Kaufmann, A Gründer, T Hadlich, J Wehrle, M Gothwal, R Bogeska, ... Journal of Experimental Medicine 209 (1), 35-50, 2012 | 87 | 2012 |
| BCL-XL expression is essential for human erythropoiesis and engraftment of hematopoietic stem cells S Afreen, S Bohler, A Müller, EM Demmerath, JM Weiss, JS Jutzi, ... Cell Death & Disease 11 (1), 8, 2020 | 48 | 2020 |
| Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms JC Peeken, JS Jutzi, J Wehrle, C Koellerer, HF Staehle, H Becker, ... Blood, The Journal of the American Society of Hematology 131 (18), 2065-2073, 2018 | 41 | 2018 |
| Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations JS Jutzi, T Basu, M Pellmann, S Kaiser, D Steinemann, MA Sanders, ... Blood, The Journal of the American Society of Hematology 133 (16), 1766-1777, 2019 | 36 | 2019 |
| Remodeling the bone marrow microenvironment–a proposal for targeting pro-inflammatory contributors in MPN JS Jutzi, A Mullally Frontiers in Immunology 11, 2093, 2020 | 24 | 2020 |
| The hen or the egg: inflammatory aspects of murine MPN models JS Jutzi, HL Pahl Mediators of Inflammation 2015 (1), 101987, 2015 | 16 | 2015 |
| Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNs JS Jutzi, AE Marneth, M Ciboddo, A Guerra-Moreno, MJ Jiménez-Santos, ... Blood, The Journal of the American Society of Hematology 140 (11), 1291-1304, 2022 | 12 | 2022 |
| Enhanced expression of the sphingosine-1-phosphate-receptor-3 causes acute myelogenous leukemia in mice S Vorbach, A Gründer, F Zhou, C Koellerer, JS Jutzi, M Simoni, L Riccetti, ... Leukemia 34 (3), 721-734, 2020 | 10 | 2020 |
| CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response JS Jutzi, AE Marneth, MJ Jiménez-Santos, J Hem, A Guerra-Moreno, ... Leukemia 37 (2), 359-369, 2023 | 7 | 2023 |
| The cross marks the spot: the emerging role of JmjC domain-containing proteins in myeloid malignancies HF Staehle, HL Pahl, JS Jutzi Biomolecules 11 (12), 1911, 2021 | 7 | 2021 |
| Method for the diagnosis of myeloid neoplasias and solid tumors H Pahl, J Jutzi US Patent 9,695,480, 2017 | 7 | 2017 |
| Jmjd1c is dispensable for healthy adult hematopoiesis and Jak2V617F-driven myeloproliferative disease initiation in mice HF Staehle, J Heinemann, A Gruender, AM Omlor, HL Pahl, JS Jutzi Plos one 15 (2), e0228362, 2020 | 6 | 2020 |
| The histone demethylase JMJD2C constitutes a novel NFE2 target gene that is required for the survival of JAK2V617F mutated cells AM Staehle, JC Peeken, G Vladimirov, ME Hoeness, S Bojtine Kovacs, ... Leukemia 37 (4), 919-923, 2023 | 3 | 2023 |
| Updated Findings of a Phase II Study of Ruxolitinib Pre-, during-and Post-Hematopoietic Stem Cell Transplantation for Patients with Primary or Secondary Myelofibrosis GS Hobbs, HT Kim, S O'Connor, MA Schroeder, R Tamari, SA Wall, ... Blood 142, 2103, 2023 | 2 | 2023 |
| Effectiveness of LSD1 inhibition for the treatment of MPN JS Jutzi, H Rienhoff, HL Pahl Haematologica 102, 148-148, 2017 | 2 | 2017 |
| Two to tango! IL-13 and TGF-β drive myelofibrosis JS Jutzi, A Mullally Blood, The Journal of the American Society of Hematology 140 (26), 2767-2768, 2022 | 1 | 2022 |
